Patch adhesiveness study

Completed

• Conditions: ziekte van Parkinson en rustelood been syndroom; Parkinson disease and Restless Legs Syndrome

• Registration Number: NL-OMON36856
• Lead Sponsor: CB Pharma

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 52

Inclusion Criteria

Healthy males and females
18-55 years
BMI 19-28 incl

Exclusion Criteria

Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Adhesiveness: the average adhesiveness score of 2 days of 24-hour patch<br /><br>application as rated by the investigator<br /><br><br /><br>Safety: adverse events, vital signs, ECG-parameters, laboratory parameters,<br /><br>skin assessments, physical examination, the C-SSRS</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Patch adhesiveness over 24 hours of patch application and immediately after<br /><br>patch application </p><br>